HEMODYNAMIC EFFECTS OF DOBUTAMINE & MILRINONE
多巴酚丁胺的血流动力学效应
基本信息
- 批准号:6304891
- 负责人:
- 金额:$ 0.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-12-01 至 2001-02-28
- 项目状态:已结题
- 来源:
- 关键词:beta antiadrenergic agent clinical research cyclic AMP dobutamine drug interactions drug screening /evaluation gene expression heart disorder chemotherapy heart failure hemodynamics human subject human therapy evaluation idiopathic dilated cardiomyopathy pharmacokinetics phosphodiesterase inhibitors
项目摘要
Chronic heart failure is often characterized by cardiac muscle cell contractile dysfunction, which is likely caused by alterations in heart muscle cell gene expression. Studies with cultured heart muscle cells have revealed fundamental differences in the gene expression programs leading to several different types of heart muscle cell failure. One common type of heart muscle failure has been associated with alterations in genes regulating hormone receptor function. In the failing human heart, there is a reduction in the number of a specific hormone receptor, designated the beta1-adrenergic receptor, and signaling failure normally mediated through a second receptor, designated the beta2-adrenergic receptor. These changes may serve to protect heart muscle cells, but they also diminish the ability of the heart muscle pump to respond to normal factors that would improve contractility in times of physical stress. Revolutionary studies performed by Dr. Gilbert and his associate, Dr. Bristow (now at the University of Colorado), demonstrated that treating heart failure with drugs that block the activity of b-adrenergic receptors leads to improvement in function of the heart pump. This study is designed to test the effects of a b-adrenergic receptor-blocking drug (dobutamine) and a drug that disrupts signaling events mediated through the b-adrenergic receptor (the phosphodiesterase inhibitor, milrinone) in an effort to dissect the complex mechanisms involved as heart muscle cells develop abnormalities of contraction in patients who develop heart failure.
慢性心力衰竭通常以心肌细胞收缩功能障碍为特征,这可能是由心肌细胞基因表达的改变引起的。 对培养的心肌细胞的研究揭示了导致几种不同类型心肌细胞衰竭的基因表达程序的根本差异。 一种常见的心肌衰竭与调节激素受体功能的基因改变有关。 在衰竭的人类心脏中,特定激素受体(称为β 1-肾上腺素能受体)的数量减少,并且通常通过第二受体(称为β 2-肾上腺素能受体)介导的信号传导失败。 这些变化可能有助于保护心肌细胞,但它们也会降低心肌泵对正常因素的反应能力,这些因素会在身体压力时改善收缩力。 吉尔伯特博士和他的同事布里斯托博士(现就职于科罗拉多大学)进行的革命性研究表明,用阻断b-肾上腺素受体活性的药物治疗心力衰竭可改善心脏泵的功能。 本研究旨在测试β-肾上腺素能受体阻断药(多巴酚丁胺)和一种破坏β-肾上腺素能受体介导的信号传导事件的药物(磷酸二酯酶抑制剂,米力农)的作用,以努力剖析心力衰竭患者心肌细胞发生收缩异常的复杂机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
E MICHAEL GILBERT其他文献
E MICHAEL GILBERT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('E MICHAEL GILBERT', 18)}}的其他基金
CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE
心力衰竭的慢性 β 受体阻滞剂治疗
- 批准号:
7376447 - 财政年份:2006
- 资助金额:
$ 0.16万 - 项目类别:
CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE
心力衰竭的慢性 β 受体阻滞剂治疗
- 批准号:
7201429 - 财政年份:2005
- 资助金额:
$ 0.16万 - 项目类别:
BETA BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION (BORG)
β 受体阻滞剂对重塑和基因表达的影响 (BORG)
- 批准号:
7201422 - 财政年份:2005
- 资助金额:
$ 0.16万 - 项目类别:
Beta blocker effect on remodeling and gene expression (BORG)
β 受体阻滞剂对重塑和基因表达的影响 (BORG)
- 批准号:
7044777 - 财政年份:2004
- 资助金额:
$ 0.16万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 0.16万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别: